Alcoholic liver disease patients treated with S-adenosyl-l-methionine: An in-depth look at liver morphologic data comparing pre and post treatment liver biopsies

Le, Michael; Enbom, Elena; Traum, Peter; Medici, Valentina; Halsted, Charles H.; French, Samuel W.

doi:10.1016/j.yexmp.2013.07.003

Cited by 18 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, other agents such as S-adenosyl-L-methionine conveyed no change on liver fibrosis as assessed by histology. 279 Thus, future development of molecules targeting extracellular matrix and liver fibrosis may open novel therapeutic perspectives in chronic liver diseases including ALD. 280 Monitoring changes in liver fibrosis may be achieved by TE using Fibroscan as the most reliable non-invasive method in ALD.…”

Section: Management Of Alcohol-related Fibrosismentioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

Thursz¹,

Gual²,

Lackner³

et al. 2018

Journal of Hepatology

655

344

View full text Add to dashboard Cite

The harmful use of alcohol has been estimated to cause approximately 3.3 million deaths every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective management and treatment of alcoholic liver disease is a pertinent public health issue. In the following Clinical Practice Guidelines, the latest data on the treatment and management of alcohol-related liver disease will be reviewed and up to date recommendations for clinical management will be provided.

show abstract

Section: Management Of Alcohol-related Fibrosismentioning

confidence: 99%

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

Thursz¹,

Gual²,

Lackner³

et al. 2018

Journal of Hepatology

655

344

View full text Add to dashboard Cite

show abstract

“…It has been hypothesized that chronic alcohol consumption decreases SAM to the SAH level, leading to mitochondrial damage and endoplasmic reticulum stress. In human studies, the treatment of ALD patients with SAM or placebo has not resulted in any difference in histopathology, AST, ALT, or bilirubin level 50-51 .…”

Section: Current Therapies and Future Approachesmentioning

confidence: 94%

Pathogenesis of Alcoholic Liver Disease

Dunn

Shah

2016

Clinics in Liver Disease

161

132

View full text Add to dashboard Cite

Alcoholic Liver Disease includes a broad clinical-histological spectrum from simple steatosis, cirrhosis, acute alcoholic hepatitis with or without cirrhosis to hepatocellular carcinoma as a complication of cirrhosis. The pathogenesis of ALD can be conceptually divided into 1) Ethanol mediated liver injury, 2) Inflammatory Immune response to injury, 3) Intestinal permeability and microbiome changes. Corticosteroids may improve outcomes, but this is controversial and probably only impacts short-term survival. New pathophysiology-based therapies are under study, including IL22, anakinra, and others. These studies provide hope for better future outcomes for this difficult disease.

show abstract

“…In animal models, SAM supplementation can reverse liver injury and mitochondrial damage caused by alcohol[ 101 ]. However, no significant difference between SAM supplementation and placebo groups has been reported[ 102 , 103 ]. Betaine, a nutrient involved in the formation of glutathione, is effective in protecting against damage from chronic alcohol consumption[ 104 , 105 ].…”

Section: Therapeutic Interventionmentioning

confidence: 99%

Alcoholic liver disease: Current insights into cellular mechanisms

Petagine¹,

Zariwala²,

Patel³

2021

WJBC

View full text Add to dashboard Cite

Alcoholic liver disease (ALD) due to chronic alcohol consumption is a significant global disease burden and a leading cause of mortality. Alcohol abuse induces a myriad of aberrant changes in hepatocytes at both the cellular and molecular level. Although the disease spectrum of ALD is widely recognized, the precise triggers for disease progression are still to be fully elucidated. Oxidative stress, mitochondrial dysfunction, gut dysbiosis and altered immune system response plays an important role in disease pathogenesis, triggering the activation of inflammatory pathways and apoptosis. Despite many recent clinical studies treatment options for ALD are limited, especially at the alcoholic hepatitis stage. We have therefore reviewed some of the key pathways involved in the pathogenesis of ALD and highlighted current trials for treating patients.

show abstract

Alcoholic liver disease patients treated with S-adenosyl-l-methionine: An in-depth look at liver morphologic data comparing pre and post treatment liver biopsies

Cited by 18 publications

References 12 publications

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

Pathogenesis of Alcoholic Liver Disease

Alcoholic liver disease: Current insights into cellular mechanisms

Contact Info

Product

Resources

About